| Catalogue Number | 153288 |
| Bacterial Resistance | Kanamycin |
| Vector Type | pcDNA 3.1 |
| Synonyms | Nitric Oxide Synthase |
| Antigen/Gene or Protein Targets | Inducible Nitric Oxide Synthase |
| Relevance |
phOC-iNOS Plasmid is a human nitric oxide synthase (iNOS) transgene driven by a human osteocalcin (hOC) promoter to control inducible nitric oxide synthase (iNOS) transgene expression in hormone refractory prostate cancer (HRPC). The plasmid was originally developed as an anti-cancer therapeutic with a view to a gene therapy strategies. Studies in the literature have demonstrated that this plasmid increases iNOS protein and total nitrite levels in PC3 and DU145 cells, but not LNCaP or HT29 (McCarthy et al., 2007). The plasmid serves as a useful tool in cardiovascular studies or any physiology associated with vasodilation. |
| Research Area | Cancer, Metabolism, Neurobiology |
| Notes |
Recommended for transpormation in DH5 alpha bacterial cells iNOS gene is 4.4kb |
Invented by Dr Helen McCarthy at Queen's University Belfast
McCarthy et al. 2007. J Gene Med. 9(6):511-20. PMID: 17471586.
Human osteocalcin: a strong promoter for nitric oxide synthase gene therapy, with specificity for hormone refractory prostate cancer.
Europe PMC ID: 17471586
McCarthy et al. 2007. J Gene Med. 9(6):511-20. PMID: 17471586.
Human osteocalcin: a strong promoter for nitric oxide synthase gene therapy, with specificity for hormone refractory prostate cancer.
